vs
CORCEPT THERAPEUTICS INC（CORT）与史密斯威森（SWBI）财务数据对比。点击上方公司名可切换其他公司
CORCEPT THERAPEUTICS INC的季度营收约是史密斯威森的1.6倍（$202.1M vs $124.7M），CORCEPT THERAPEUTICS INC净利率更高（12.0% vs 1.5%，领先10.5%），CORCEPT THERAPEUTICS INC同比增速更快（11.1% vs -3.9%），CORCEPT THERAPEUTICS INC自由现金流更多（$38.4M vs $16.3M），过去两年CORCEPT THERAPEUTICS INC的营收复合增速更高（17.3% vs -4.8%）
Corcept Therapeutics是一家制药企业，专注于严重代谢疾病、精神疾病及肿瘤疾病治疗药物的发现、开发与商业化。公司围绕皮质醇过量带来的不良影响展开研究，致力于开发可缓解相关症状的新型化合物，管理团队由首席执行官兼总裁、董事Joseph K. Belanoff医学博士领导。
史密斯韦森品牌公司是总部位于美国田纳西州玛丽维尔的美国枪械制造商，是美国历史悠久的知名枪械生产企业，在民用和执法枪械领域拥有较高的市场知名度。
CORT vs SWBI — 直观对比
营收规模更大
CORT
是对方的1.6倍
$124.7M
营收增速更快
CORT
高出15.0%
-3.9%
净利率更高
CORT
高出10.5%
1.5%
自由现金流更多
CORT
多$22.1M
$16.3M
两年增速更快
CORT
近两年复合增速
-4.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $202.1M | $124.7M |
| 净利润 | $24.3M | $1.9M |
| 毛利率 | 98.7% | 24.3% |
| 营业利润率 | 2.2% | 3.3% |
| 净利率 | 12.0% | 1.5% |
| 营收同比 | 11.1% | -3.9% |
| 净利润同比 | -21.0% | -53.6% |
| 每股收益（稀释后） | $0.20 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CORTSWBI
| Q4 25 | $202.1M | $124.7M | ||
| Q3 25 | $207.6M | $85.1M | ||
| Q2 25 | $194.4M | $140.8M | ||
| Q1 25 | $157.2M | $115.9M | ||
| Q4 24 | $181.9M | $129.7M | ||
| Q3 24 | $182.5M | $88.3M | ||
| Q2 24 | $163.8M | $159.1M | ||
| Q1 24 | $146.8M | $137.5M |
净利润CORTSWBI
| Q4 25 | $24.3M | $1.9M | ||
| Q3 25 | $19.7M | $-3.4M | ||
| Q2 25 | $35.1M | $8.6M | ||
| Q1 25 | $20.5M | $2.1M | ||
| Q4 24 | $30.7M | $4.5M | ||
| Q3 24 | $47.2M | $-1.9M | ||
| Q2 24 | $35.5M | $27.9M | ||
| Q1 24 | $27.8M | $7.9M |
毛利率CORTSWBI
| Q4 25 | 98.7% | 24.3% | ||
| Q3 25 | 97.8% | 25.9% | ||
| Q2 25 | 98.2% | 28.8% | ||
| Q1 25 | 98.5% | 24.1% | ||
| Q4 24 | 98.4% | 26.6% | ||
| Q3 24 | 98.4% | 27.4% | ||
| Q2 24 | 98.5% | 35.5% | ||
| Q1 24 | 98.3% | 28.7% |
营业利润率CORTSWBI
| Q4 25 | 2.2% | 3.3% | ||
| Q3 25 | 4.9% | -3.5% | ||
| Q2 25 | 13.7% | 9.3% | ||
| Q1 25 | 2.2% | 4.1% | ||
| Q4 24 | 13.9% | 5.8% | ||
| Q3 24 | 25.5% | -1.7% | ||
| Q2 24 | 21.7% | 17.4% | ||
| Q1 24 | 20.1% | 8.2% |
净利率CORTSWBI
| Q4 25 | 12.0% | 1.5% | ||
| Q3 25 | 9.5% | -4.0% | ||
| Q2 25 | 18.1% | 6.1% | ||
| Q1 25 | 13.1% | 1.8% | ||
| Q4 24 | 16.9% | 3.5% | ||
| Q3 24 | 25.9% | -2.1% | ||
| Q2 24 | 21.7% | 17.5% | ||
| Q1 24 | 18.9% | 5.7% |
每股收益（稀释后）CORTSWBI
| Q4 25 | $0.20 | $0.04 | ||
| Q3 25 | $0.16 | $-0.08 | ||
| Q2 25 | $0.29 | $0.19 | ||
| Q1 25 | $0.17 | $0.05 | ||
| Q4 24 | $0.25 | $0.10 | ||
| Q3 24 | $0.41 | $-0.04 | ||
| Q2 24 | $0.32 | $0.60 | ||
| Q1 24 | $0.25 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $372.2M | $22.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $647.8M | $363.2M |
| 总资产 | $836.7M | $548.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CORTSWBI
| Q4 25 | $372.2M | $22.4M | ||
| Q3 25 | $421.7M | $18.0M | ||
| Q2 25 | $342.2M | $25.2M | ||
| Q1 25 | $322.8M | $26.7M | ||
| Q4 24 | $383.3M | $39.1M | ||
| Q3 24 | $380.3M | $35.5M | ||
| Q2 24 | $473.2M | $60.8M | ||
| Q1 24 | $410.8M | $47.4M |
股东权益CORTSWBI
| Q4 25 | $647.8M | $363.2M | ||
| Q3 25 | $631.9M | $364.4M | ||
| Q2 25 | $635.8M | $372.5M | ||
| Q1 25 | $683.3M | $366.9M | ||
| Q4 24 | $679.6M | $371.5M | ||
| Q3 24 | $638.8M | $380.0M | ||
| Q2 24 | $596.2M | $399.9M | ||
| Q1 24 | $547.9M | $376.4M |
总资产CORTSWBI
| Q4 25 | $836.7M | $548.6M | ||
| Q3 25 | $823.6M | $554.6M | ||
| Q2 25 | $801.7M | $559.6M | ||
| Q1 25 | $846.5M | $578.9M | ||
| Q4 24 | $840.6M | $587.4M | ||
| Q3 24 | $784.3M | $571.3M | ||
| Q2 24 | $714.6M | $577.4M | ||
| Q1 24 | $655.9M | $570.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.4M | $27.3M |
| 自由现金流经营现金流 - 资本支出 | $38.4M | $16.3M |
| 自由现金流率自由现金流/营收 | 19.0% | 13.1% |
| 资本支出强度资本支出/营收 | 0.0% | 8.8% |
| 现金转化率经营现金流/净利润 | 1.58× | 14.22× |
| 过去12个月自由现金流最近4个季度 | — | $21.3M |
8季度趋势，按日历期对齐
经营现金流CORTSWBI
| Q4 25 | $38.4M | $27.3M | ||
| Q3 25 | $54.5M | $-8.1M | ||
| Q2 25 | $43.9M | $40.8M | ||
| Q1 25 | $5.1M | $-9.8M | ||
| Q4 24 | $59.3M | $-7.4M | ||
| Q3 24 | $73.8M | $-30.8M | ||
| Q2 24 | $41.2M | $43.7M | ||
| Q1 24 | $23.8M | $25.2M |
自由现金流CORTSWBI
| Q4 25 | $38.4M | $16.3M | ||
| Q3 25 | — | $-12.4M | ||
| Q2 25 | $43.9M | $33.5M | ||
| Q1 25 | $5.0M | $-16.1M | ||
| Q4 24 | $59.2M | $-10.7M | ||
| Q3 24 | $72.2M | $-35.5M | ||
| Q2 24 | $40.8M | $38.2M | ||
| Q1 24 | — | $7.0M |
自由现金流率CORTSWBI
| Q4 25 | 19.0% | 13.1% | ||
| Q3 25 | — | -14.6% | ||
| Q2 25 | 22.6% | 23.8% | ||
| Q1 25 | 3.2% | -13.9% | ||
| Q4 24 | 32.5% | -8.3% | ||
| Q3 24 | 39.5% | -40.2% | ||
| Q2 24 | 24.9% | 24.0% | ||
| Q1 24 | — | 5.1% |
资本支出强度CORTSWBI
| Q4 25 | 0.0% | 8.8% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | 0.0% | 5.2% | ||
| Q1 25 | 0.1% | 5.4% | ||
| Q4 24 | 0.1% | 2.5% | ||
| Q3 24 | 0.9% | 5.3% | ||
| Q2 24 | 0.3% | 3.5% | ||
| Q1 24 | 0.0% | 13.2% |
现金转化率CORTSWBI
| Q4 25 | 1.58× | 14.22× | ||
| Q3 25 | 2.77× | — | ||
| Q2 25 | 1.25× | 4.73× | ||
| Q1 25 | 0.25× | -4.68× | ||
| Q4 24 | 1.93× | -1.63× | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.16× | 1.57× | ||
| Q1 24 | 0.86× | 3.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
